Functional heterogeneity of Nadph oxidases in atherosclerotic and aneurysmal diseases

Journal of Atherosclerosis and Thrombosis

Volumn 24, Issue 1, 2017, Pages 1-13

  Kigawa, Yasuyoshi ^a   Miyazaki, Takuro ^b   Lei, Xiao Feng ^b   Kim Kaneyama, Joo Ri ^b   Miyazaki, Akira ^b  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Abdominal aortic aneurysm; Aortic dissection; Atherosclerosis; Nadph oxidase

Indexed keywords

REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; UNCLASSIFIED DRUG;

ANEURYSM; AORTA DISSECTION; ATHEROSCLEROSIS; BIOAVAILABILITY; CELL ADHESION; CELL MOTILITY; CLINICAL TRIAL (TOPIC); ENZYME POLYMORPHISM; GENE TARGETING; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION; ANIMAL; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ANEURYSM; ANIMALS; ATHEROSCLEROSIS; HUMANS; NADPH OXIDASE;

EID: 85008352122     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.33431     Document Type: Review

References (97)

1. Bedard K, Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 2007; 87: 245-313
2. Lassègue B, Clempus RE: Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol, 2003; 285: R277-R297
3. Lassègue B, Griendling KK: NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol, 2010; 30: 653-661
4. Royer-Pokora B, Kunkel LM, Monaco AP, Goff SC, Newburger PE, Baehner RL, Cole FS, Curnutte JT, Orkin SH: Cloning the gene for an inherited human disorder—chronic granulomatous disease—on the basis of its chromosomal location. Nature, 1986; 322: 32-38
5. Teahan C, Rowe P, Parker P, Totty N, Segal AW: The X-linked chronic granulomatous disease gene codes for the beta-chain of cytochrome b-245. Nature, 1987; 327: 720-721
6. Tsunawaki S, Mizunari H, Namiki H, Kuratsuji T: NADPH-binding component of the respiratory burst oxidase system: studies using neutrophil membranes from patients with chronic granulomatous disease lacking the beta-subunit of cytochrome b558. J Exp Med, 1994; 179: 291-297
7. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM: NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal, 2006; 8: 691-728
8. Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med, 1999; 340: 115-126
9. Mizuno Y, Jacob RF, Mason RP: Inflammation and the development of atherosclerosis. J Atheroscler Thromb, 2011; 18: 351-358
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-504
11. Anderson RN: Deaths: leading causes for 2000. Natl Vital Stat Rep, 2002; 50: 1-85
12. Svensjö S, Björck M, Gürtelschmid M, Djavani Gidlund K, Hellberg A, Wanhainen A: Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation, 2011; 124: 1118-1123
13. Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, Gelijns AC, Greco G: Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg, 2010; 52: 539-548
14. Norman PE, Jamrozik K, Lawrence-Brown MM, Le MT, Spencer CA, Tuohy RJ, Parsons RW, Dickinson JA: Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ, 2004; 329: 1259
15. Lindholt JS, Juul S, Fasting H, Henneberg EW: Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ, 2005; 330: 750
16. Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, Thompson SG, Walker NM; Multicentre Aneurysm Screening Study Group: The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet, 2002; 360: 1531-1539
17. Heikkinen M, Salenius JP, Auvinen O: Ruptured abdominal aortic aneurysm in a well-defined geographic area. J Vasc Surg, 2002; 36: 291-296
18. Baril DT, Jacobs TS, Marin ML: Surgery insight: advances in endovascular repair of abdominal aortic aneurysms. Nat Clin Pract Cardiovasc Med, 2007; 4: 206-213
19. Schroder K, Helmcke I, Palfi K, Krause KH, Busse R, Brandes RP: Nox1 mediates basic fibroblast growth factor-induced migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2007; 27: 1736-1743
20. Lee MY, San Martin A, Mehta PK, Dikalova AE, Garrido AM, Datla SR, Lyons E, Krause KH, Banfi B, Lambeth JD, Lassegue B, Griendling KK: Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol, 2009; 29: 480-487
21. Manea A, Tanase LI, Raicu M, Simionescu M: Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol, 2010; 30: 105-112
22. Wang P, Tang F, Li R, Zhang H, Chen S, Liu P, Huang H: Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan. Pharmacol Res, 2007; 55: 408-417
23. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, Fukunaga M, Tamaki T, Kiyomoto H, Kohno M, Shokoji T, Kimura S, Abe Y: The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol, 2004; 15: 306-315
24. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D, Taylor WR, Schmidt HHW, Owens GK, Lambeth JD, Griendling KK: Nox1 overexpression potentiates angiotensin Ⅱ-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation, 2005; 112: 2668-2676
25. Miller FJ Jr, Filali M, Huss GJ, Stanic B, Chamseddine A, Barna TJ, Lamb FS: Cytokine activation of nuclear factor κB in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res, 2007; 101: 663-671
26. Haloui M, Meilhac O, Jandrot-Perrus M, Michel JB: Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin. Eur J Pharmacol, 2003; 474: 175-184
27. Csányi G, Taylor WR, Pagano PJ: NOX and inflammation in the vascular adventitia. Free Radic Biol Med, 2009; 47: 1254-1266
28. Gupte SA, Kaminski PM, George S, Kouznestova L, Olson SC, Mathew R, Hintze TH, Wolin MS: Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction. Am J Physiol Heart Circ Physiol, 2009; 296: H1048-H1057
29. Pietrowski E, Bender B, Huppert J, White R, Luhmann HJ, Kuhlmann CR: Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P) H-oxidase derived reactive oxygen species. J Vasc Res, 2011; 48: 52-58
30. Ellison MA, Thurman G, Gearheart CM, Seewald RH, Porter CC, Ambruso DR: INF-γ Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself. PLoS One, 2015; 10: e0136766
31. Takenouchi Y, Kobayashi T, Matsumoto T, Kamata K: Gender differences in age-related endothelial function in the murine aorta. Atherosclerosis, 2009; 206: 397-404
32. Park YM, Lim BH, Touyz RM, Park JB: Expression of NAD(P)H oxidase subunits and their contribution to cardiovascular damage in aldosterone/salt-induced hypertensive rat. J Korean Med Sci, 2008; 23: 1039-1045
33. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP: gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation, 2004; 109: 1795-1801
34. Fujii A, Nakano D, Katsuragi M, Ohkita M, Takaoka M, Ohno Y, Matsumura Y: Role of gp91phox-containing NADPH oxidase in the deoxycorticosterone acetate-saltinduced hypertension. Eur J Pharmacol, 2006; 552: 131-134
35. Chan EC, van Wijngaarden P, Liu GS, Jiang F, Peshavariya H, Dusting GJ: Involvement of Nox2 NADPH oxidase in retinal neovascularization. Invest Ophthalmol Vis Sci, 2013; 54: 7061-7067
36. Chen K, Kirber MT, Xiao H, Yang Y, Keaney JF Jr: Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol, 2008; 181: 1129-1139
37. Basuroy S, Bhattacharya S, Leffler CW, Parfenova H: Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol, 2009; 296: C422-C432
38. Kuroda J, Nakagawa K, Yamasaki T, Nakamura K, Takeya R, Kuribayashi F, Imajoh-Ohmi S, Igarashi K, Shibata Y, Sueishi K, Sumimoto H: The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells, 2005; 10: 1139-1151
39. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, Sorescu GP, Schmidt HH, Lassègue B, Griendling KK: Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol, 2007; 27: 42-48
40. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Fórró L, Schlegel W, Krause KH: NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J, 2007; 406: 105-114
41. Brown DI, Griendling KK: Nox proteins in signal transduction. Free Radic Biol Med, 2009; 47: 1239-1253
42. Ismail S, Sturrock A, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T, Hoidal J: NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-β1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol, 2009; 296: L489-L499
43. Djordjevic T, BelAiba RS, Bonello S, Pfeilschifter J, Hess J, Gorlach A: Human urotensin Ⅱ is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol, 2005; 25: 519-525
44. Chen K, Kirber MT, Xiao H, Yang Y, Keaney JF Jr: Regulation of ROS signal transduction by NADPH oxidase 4 localization. J Cell Biol, 2008; 181: 1129-1139
45. Wu RF, Ma Z, Myers DP, Terada LS: HIV-1 Tat activates dual Nox pathways leading to independent activation of ERK and JNK MAP kinases. J Biol Chem, 2007; 282: 37412-37419
46. Datla SR, Peshavariya H, Dusting GJ, Mahadev K, Goldstein BJ, Jiang F: Important role of Nox4 type NADPH oxidase in angiogenic responses in human microvascular endothelial cells in vitro. Arterioscler Thromb Vasc Biol, 2007; 27: 2319-2324
47. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, Sorescu GP, Schmidt HH, Lassegue B, Griendling KK: Nox4 is required for main-tenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol, 2007; 27: 42-48
48. Xiao Q, Luo Z, Pepe AE, Margariti A, Zeng L, Xu Q: Embryonic stem cell differentiation into smooth muscle cells is mediated by Nox4-produced H2O2. Am J Physiol Cell Physiol, 2009; 296: C711-C723
49. Lyle AN, Deshpande NN, Taniyama Y, Seidel-Rogol B, Pounkova L, Du P, Papaharalambus C, Lassègue B, Griendling KK: Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res, 2009; 105: 249-259
50. Haurani MJ, Cifuentes ME, Shepard AD, Pagano PJ: Nox4 oxidase overexpression specifically decreases endogenous Nox4 mRNA and inhibits angiotensin Ⅱ-induced adventitial myofibroblast migration. Hypertension, 2008; 52: 143-149
51. Schröder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP: Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res, 2012; 110: 1217-1225
52. BelAiba RS, Djordjevic T, Petry A, Diemer K, Bonello S, Banfi B, Hess J, Pogrebniak A, Bickel C, Gorlach A: NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med, 2007; 42: 446-459
53. Jagnandan D, Church JE, Banfi B, Stuehr DJ, Marrero MB, Fulton DJ: Novel mechanism of activation of NADPH oxidase 5. calcium sensitization via phosphorylation. J Biol Chem, 2007; 282: 6494-6507
54. Serrander L, Jaquet V, Bedard K, Plastre O, Hartley O, Arnaudeau S, Demaurex N, Schlegel W, Krause KH: NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie, 2007; 89: 1159-1167
55. Jay DB, Papaharalambus CA, Seidel-Rogol B, Dikalova AE, Lassegue B, Griendling KK: Nox5 mediates PDGFinduced proliferation in human aortic smooth muscle cells. Free Radic Biol Med, 2008; 45: 329-335
56. Zhang Q, Malik P, Pandey D, Gupta S, Jagnandan D, Belin de Chantemele E, Banfi B, Marrero MB, Rudic RD, Stepp DW, Fulton DJ: Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arterioscler Thromb Vasc Biol, 2008; 28: 1627-1633
57. Hansson GK, Hermansson A: The immune system in atherosclerosis. Nat Immunol, 2011; 12: 204-212
58. Sorescu D, Weiss D, Lassègue B, Clempus RE, Szöcs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK: Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation, 2002; 105: 1429-1435
59. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS: p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest, 2001; 108: 1513-1522
60. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, Jandeleit-Dahm KA: NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation, 2013; 127: 1888-1902
61. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG, Drummond GR: Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/-mice. Am J Physiol Heart Circ Physiol, 2010; 298: H24-H32
62. Poredos P, Jezovnik MK: Testing endothelial function and its clinical relevance. J Atheroscler Thromb, 2013; 20: 1-8
63. Douglas G, Bendall JK, Crabtree MJ, Tatham AL, Carter EE, Hale AB, Channon KM: Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE－/－ mice. Cardiovasc Res, 2012; 94: 20-29
64. Zhao R, Ma X, Xie X, Shen GX: Involvement of NADPH oxidase in oxidized LDL-induced upregulation of heat shock factor-1 and plasminogen activator inhibitor-1 in vascular endothelial cells. Am J Physiol Endocrinol Metab, 2009; 297: E104-E111
65. Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, Miller YI: Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4-and spleen tyrosine kinasedependent activation of NADPH oxidase 2. Circ Res, 2009; 104: 210-218
66. Sobey CG, Judkins CP, Rivera J, Lewis CV, Diep H, Lee HW, Kemp-Harper BK, Broughton BR, Selemidis S, Gaspari TA, Samuel CS, Drummond GR: NOX1 deficiency in apolipoprotein E-knockout mice is associated with elevated plasma lipids and enhanced atherosclerosis. Free Radic Res, 2015; 49: 186-198
67. Schürmann C, Rezende F, Kruse C, Yasar Y, Löwe O, Fork C, van de Sluis B, Bremer R, Weissmann N, Shah AM, Jo H, Brandes RP, Schröder K: The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur Heart J, 2015; 36: 3447-3456
68. Adiguzel E, Ahmad PJ, Franco C, Bendeck MP: Collagens in the progression and complications of atherosclerosis. Vasc Med, 2009; 14: 73-89
69. Shami A, Gonçalves I, Hultgårdh-Nilsson A: Collagen and related extracellular matrix proteins in atherosclerotic plaque development. Curr Opin Lipidol, 2014; 25: 394-399
70. Katsuda S, Kaji T: Atherosclerosis and extracellular matrix. J Atheroscler Thromb, 2003; 10: 267-274
71. Manea A, Manea SA, Gan AM, Constantin A, Fenyo IM, Raicu M, Muresian H, Simionescu M: Human monocytes and macrophages express NADPH oxidase 5; a potential source of reactive oxygen species in atherosclerosis. Biochem Biophys Res Commun, 2015; 461: 172-179
72. Brown DI, Griendling KK: Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res, 2015; 116: 531-549
73. Fukai T, Ushio-Fukai M: Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal, 2011; 15: 1583-1606
74. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, Tsuchihashi M, Sugaya T, Charo IF, Kura S, Tsuzuki T, Ishibashi T, Takeshita A, Egashira K: Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res, 2004; 94: 1203-1210
75. Tribble DL, Gong EL, Leeuwenburgh C, Heinecke JW, Carlson EL, Verstuyft JG, Epstein CJ: Fatty streak formation in fat-fed mice expressing human copper-zinc superoxide dismutase. Arterioscler Thromb Vasc Biol, 1997; 17: 1734-1740
76. Ballinger SW, Patterson C, Knight-Lozano CA, Burow DL, Conklin CA, Hu Z, Reuf J, Horaist C, Lebovitz R, Hunter GC, McIntyre K, Runge MS: Mitochondrial integrity and function in atherogenesis. Circulation, 2002; 106: 544-549
77. Strålin P, Karlsson K, Johansson BO, Marklund SL: The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol, 1995; 15: 2032-2036
78. Fukai T, Galis ZS, Meng XP, Parthasarathy S, Harrison DG: Vascular expression of extracellular superoxide dismutase in atherosclerosis. J Clin Invest, 1998; 101: 2101-2111
79. Sentman ML, Brännström T, Westerlund S, Laukkanen MO, Ylä-Herttuala S, Basu S, Marklund SL: Extracellular superoxide dismutase deficiency and atherosclerosis in mice. Arterioscler Thromb Vasc Biol, 2001; 21: 1477-1482
80. McCormick ML, Gavrila D, Weintraub NL: Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol, 2007; 27: 461-469
81. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT: Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest, 2002; 110: 625-632
82. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, Moons L: Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation, 2004; 109: 1408-1414
83. Gavrila D, Li WG, McCormick ML, Thomas M, Daugherty A, Cassis LA, Miller FJ Jr, Oberley LW, Dellsperger KC, Weintraub NL: Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin Ⅱ-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2005; 25: 1671-1677
84. Ejiri J, Inoue N, Tsukube T, Munezane T, Hino Y, Kobayashi S, Hirata K, Kawashima S, Imajoh-Ohmi S, Hayashi Y, Yokozaki H, Okita Y, Yokoyama M: Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin Ⅱ type 1 receptor blocker. Cardiovasc Res, 2003; 59: 988-996
85. Guzik B, Sagan A, Ludew D, Mrowiecki W, Chwała M, Bujak-Gizycka B, Filip G, Grudzien G, Kapelak B, Zmudka K, Mrowiecki T, Sadowski J, Korbut R, Guzik TJ: Mechanisms of oxidative stress in human aortic aneurysms—association with clinical risk factors for atherosclerosis and disease severity. Int J Cardiol, 2013; 168: 2389-2396
86. Saraff K, Babamusta F, Cassis LA, Daugherty A: Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin Ⅱ-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 2003; 23: 1621-1626
87. Bruemmer D, Daugherty A, Lu H, Rateri DL: Relevance of angiotensin Ⅱ-induced aortic pathologies in mice to human aortic aneurysms. Ann N Y Acad Sci, 2011; 1245: 7-10
88. Thomas M, Gavrila D, McCormick ML, Miller FJ Jr, Daugherty A, Cassis LA, Dellsperger KC, Weintraub NL: Deletion of p47phox attenuates angiotensin Ⅱ-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation, 2006; 114: 404-413
89. Gavazzi G, Deffert C, Trocme C, Schäppi M, Herrmann FR, Krause KH: NOX1 deficiency protects from aortic dissection in response to angiotensin Ⅱ. Hypertension, 2007; 50: 189-196
90. Fan LM, Douglas G, Bendall JK, McNeill E, Crabtree MJ, Hale AB, Mai A, Li JM, McAteer MA, Schneider JE, Choudhury RP, Channon KM: Endothelial cell-specific reactive oxygen species production increases susceptibility to aortic dissection. Circulation, 2014; 129: 2661-2672
91. Kigawa Y, Miyazaki T, Lei XF, Nakamachi T, Oguchi T, Kim-Kaneyama JR, Taniyama M, Tsunawaki S, Shioda S, Miyazaki A: NADPH oxidase deficiency exacerbates angiotensin Ⅱ-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol, 2014; 34: 2413-2420
92. Zhang WJ, Wei H, Frei B: Genetic deficiency of NADPH oxidase does not diminish, but rather enhances, LPSinduced acute inflammatory responses in vivo. Free Radic Biol Med, 2009; 46: 791-798
93. Deffert C, Carnesecchi S, Yuan H, Rougemont AL, Kelkka T, Holmdahl R, Krause KH, Schäppi MG: Hyperinflammation of chronic granulomatous disease is abolished by NOX2 reconstitution in macrophages and dendritic cells. J Pathol, 2012; 228: 341-350
94. van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, Netea MG: Reactive oxygen species-independent activation of the IL-1β inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A, 2010; 107: 3030-3033
95. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T: Apelin signaling antagonizes Ang Ⅱ effects in mouse models of atherosclerosis. J Clin Invest, 2008; 118: 3343-3354
96. Bengtsson SH, Gulluyan LM, Dusting GJ, Drummond GR: Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clin Exp Pharmacol Physiol, 2003; 30: 849-854
97. Steinhubl SR: Why have antioxidants failed in clinical trials? Am J Cardiol, 2008; 22: 101: 14D-19D